Abstract
Peltenburg et al (Circulation 2022;145:333–344, PMID 34874747) investigated the association between risk for arrhythmic events and type of β-blocker in 329 symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT). RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and start of β-blocker therapy <18 years of age) from both the International CPVT Registry and the PACES Pediatric CPVT Registry were enrolled.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
